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Abstract
Our aim was to synthesize the published literature on factors that potentially affect the delivery of bronchodilators using valved
holding chambers (VHC) in preschool children. We also aimed to identify those attributes that are not yet incorporated or clearly
stated in the guidelines and those topics that are still lacking sufficient data. There is strong evidence supporting several
recommendations in current guidelines. Based on present knowledge, bronchodilators should be delivered by VHC administer-
ing each puff separately. Face mask should be omitted as soon as the child can hold the mouthpiece of the VHC tightly between
the lips and teeth. Based on the review, we suggest adding a specific note to current guidelines about the effect of chamber
volume and the impact of co-operation during drug administration. Calming the child and securing a tight face-to-mask seal is
critical for successful drug delivery. There is not enough evidence to make specific recommendations on the most reliable VHC
and face mask for children. There is an urgent need for studies that evaluate and compare the effectiveness of VHCs in various
clinical settings in wide age-groups and respiratory patterns. In addition, there is insufficient data on ideal chamber volume,
material, and effective antistatic treatment.
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What is Known:
• Valved holding chambers (VHC) should not be considered interchangeable when used with pressurized metered dose inhalers (pMDI).
• Drug delivery is influenced by VHC volume, aerodynamic and electrostatic properties; mask fit; respiratory pattern and co-operation during
inhalation; and the number of puffs actuated.
What is New:
• The impact of co-operation, VHC volume, and good mask-to-face fit during drug inhalation is not stressed enough in the guidelines.
• Studies are urgently needed to evaluate the effectiveness of different VHCs in various clinical settings focusing on VHC electrostatic properties,
respiratory patters, face masks, and ideal pMDI+VHC combinations.
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Introduction
Acute bronchoconstriction and viral wheezing account for ap-
proximately 10% of the emergency room (ER) visits in chil-
dren resulting in hospitalization in 30–50% of cases [1, 2].
Bronchodilators administered by pressurized metered dose in-
halers (pMDI) via valved holding chambers (VHC) are clini-
cally at least as effective as nebulizers [2–7]. Although most
current guidelines recommend the use of VHC for the delivery
of bronchodilators in acute bronchial obstruction in young
children [8–14], nebulizers are still widely used. In the era of
coronavirus disease 2019 (COVID-19) pandemic, there is
considerable concern about the potential risk of transmission
the virus in the form of aerosolized respiratory droplets by
nebulizers [15, 16], although preschool children are not the
main spreaders of COVID-19. Consequently, the use of
metered-dose inhalers (MDIs) have increased considerably
as an alternative to nebulized therapy.
In clinical practice, the most reliable and effective VHC
delivery system—with and without face masks—and optimal
dosing regimen of bronchodilators should be used. However,
each VHC has its own unique features related to material,
electrostatic and aerodynamic properties, volume, dead space,
and valve design. Furthermore, the face mask fit and crying
during inhalation administration may affect the treatment
efficacy.
Our aim was to synthesize the published literature on fac-
tors that potentially affect the delivery of bronchodilators
using valved holding chambers (VHC) in preschool children.
We also aimed to identify those attributes with sufficient ev-
idence that are not yet incorporated or clearly stated in the
guidelines, and those topics that are still lacking sufficient
data.
Review of the literature
We searched the following electronic databases up to October
25, 2020, to capture systematic reviews and individual trials:
Medline (OVID), US National Library of Medicine PubMed,
Cochrane Database of Systematic Reviews, Duodecim
Terveysportti database in Finland, Google Scholar, and
Google internet search engine. The following search terms
were used: nebulizer, nebuliser, spacer or valved holding
chamber in combination with any of the following: antistatic,
static, washing, priming, mask, face mask, facemask, seal, fit,
wheezing, asthma, salbutamol, albuterol, bronchodilator, be-
ta-sympathomimetic(s) number of puffs, guideline, and
review. The search was limited to English and Finnish lan-
guage publications. In addition to searching the electronic
databases, we screened the reference lists from the already
identified studies, review articles, and guidelines for any ad-
ditional studies. There were 3221 records with abstract
identified. After the duplicates were removed, 3092 records
were screened, and 2928 records were excluded. Altogether
124 full-text articles were assessed for eligibility, and 66 full-
text articles were excluded. Finally, 58 studies were included
in the synthesis.
Delivered dose of bronchodilators with different
types of VHC
Each VHC has its own unique features related to material,
electrostatic and aerodynamic characteristics, volume, dead
space, and valve design [17–21] (Table 1). Thus, certain com-
binations of pMDI+VHC may result in marked differences in
dose output [18, 19, 21–27]. For example, using tidal volume
Vt 50 ml and RR 30/min Mitchell et al. [24] found that one of
the three VHCs investigated (Space Chamber, Vent-170 and
Child AeroChamber) yielded undetectable levels of
salbutamol compared to 37μg filter dose from another device.
A recent study observed markedly better salbutamol delivery
with Optiochamber Diamond compared to Babyhaler espe-
cially with Vt below 150 mL [28]. In addition, similar devices
from different brands may have up to 20-fold differences in
drug delivery capacity in experimental in vitro models [17,
20].
The review of the literature showed that VHCs are not
interchangeable and recommended drug doses may have to
be adjusted according to the properties of each pMDI+VHC
combination. However, there is insufficient evidence regard-
ing the clinically most effective VHC. This is reflected in the
current lack of standardization and variations in the use of
these devices. There are no specific recommendations in the
guidelines about VHC models (Table 2).
Impact of VHC volume on the output of
bronchodilators
In children, larger volume VHCs (> 200 mL) may result in a
lower salbutamol output compared with smaller VHCs (< 200
mL) [17, 22, 27, 29]. In large volume VHCs, the aerosol
concentration and particle impaction are less than in a smaller
volume VHC. This can result in lower inhaled doses at a
decreased Vt but higher doses when the VHC can be emptied
faster with a larger Vt [29–33]. During bronchoconstriction,
Vt decreases and RR increases, and asthmatic patients have a
higher range of variation in PIFR compared to healthy sub-
jects [34]. Operation of VHCs under suboptimal conditions is
clinically important since children below school age can have
inspiratory flow rates as low as 2 L/min [34]. Only the GINA
guidelines [9] indicate that using spacers with less than
350-mL chamber volume is advantageous in very young chil-
dren (Table 2).
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Effect of the respiratory pattern on drug delivery
through VHCs
Drug delivery through VHCs is shown to be dependent on the
breathing pattern and respiratory characteristics of the pa-
tients, both in vivo and in experimental models [17, 29–33,
35]. Inspiratory flow rate (PIFR) is linearly correlated with Vt
[29, 34] and asthmatic patients have a wider range of PIFR
compared with healthy subjects [34].
Increasing Vt is associated with increasing drug delivery.
Chavez and colleagues [36] found in an in vitro study using
AeroChamber Max® that when gradually increasing the Vt
from 36 to 290 ml, the filter dose of albuterol increased in a
logarithmic fashion with both RRs of 12 and 24 L/min.
During bronchoconstriction, Vt decreases and respira-
tory rate (RR) increases. The drug delivery capacity
seems to be sensitive to shallow and rapid respiratory
pattern related to airway obstruction [17, 22]. For exam-
ple, with Vt of 30–50 ml and RR of 25–30/min, some
VHCs yielded undetectable in vitro filter doses of
salbutamol [22, 24].
Mitchell et al. [24] observed marked differences in the
effect of breathing patterns on drug delivery between three
VHC devices. At low tidal volume (50 ml), no salbutamol
was delivered by either the Vent 170 or Space ChamberTM,
whereas the unit dose from the AeroChamber®was 39.7 ± 1.6
μg. The Vent-170 and Spacer ChamberTM delivered measur-
able doses for salbutamol when the tidal volume was in-
creased to 100 ml and to 200 ml; however, the corresponding
doses available from the AeroChamber® was always signifi-
cantly greater [24].
We did not find clinical data comparing different VHCs in
small children with severe bronchial obstruction having very
low Vt and high RR. The effect of variable respiratory pattern
Table 1 Characteristics of some valved holding chambers (VHC) on
the market worldwide. Each device has its own range of face masks.
Disposable cardboard VHCs are not compatible with any mask. Face
masks vary considerably in volume (40–100 ml), softness and fit.





and static charge specified
by the manufacturer*
Valve characteristics and additional features
A2A Spacer (A2A) 210 mL ABS, antistatic Internal circular unidirectional silicon valve, aerosol passes through the
valve centrally
Aerochamber plus 149 mL ABS, antistatic Internal circular unidirectional silicon valve, aerosol passes at the valve
periphery, top outside inspiratory indicator
Babyhaler 350 mL Polycarbonate,
non-electrostatic
Internal circular unidirectional silicon valve hinged centrally, aerosol passes
at the valve periphery, additional top outside valve
Compact Space Chamber Plus 160 mL ABS, antistatic Internal silicon valve with central cross shaped opening
DispoZABLE spacer N/A Cardboard No valve. No Mask.
InspiraChamber N/A ABS, antistatic Internal cone shaped unidirectional silicon valve, aerosol passes through the
valve centrally
LiteAire Disposable N/A Cardboard Dual plastic sheet valves. Disposable spacer. No mask.
Livingstone Disposable
Cardboard Asthma Spacer
N/A Cardboard Dual plastic sheet valves. Disposable spacer. No mask.
Optichamber diamond 140 mL ABS, antistatic Internal cone shaped unidirectional silicon valve, aerosol passes through the
valve centrally, additional top outside expiratory valve
ProChamber 145 mL ABS, antistatic Internal cone shaped unidirectional silicon valve, aerosol passes through the
valve centrally
Rossmax Aero Spacer 175 mL ABS, antistatic Internal circular unidirectional silicon valve, aerosol passes through the
valve centrally
Tipshaler N/A N/A Internal cone shaped unidirectional silicon valve, aerosol passes through the
valve centrally
Volumatic 750 mL Polycarbonate,
non-electrostatic
Internal rigid circular plastic valve, aerosol passes at the valve periphery.
No mask.
Vortex 194 mL Aluminum, reduced static
charge
Internal cone shaped unidirectional silicon valve, aerosol passes through the
valve centrally
*Manufacturers use several different terms: antistatic, non-electrostatic or reduced static charge. All non-conductive materials (such as ABS, polycar-
bonate, and cardboard) are prone to accumulate electrostatic charge.
ABS, acrylonitrile butadiene styrene
N/A, not available
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Table 2 Overview of the current treatment guidelines of optimal administration of bronchodilators with valved hold chambers (VHCs) in preschool
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by age and during bronchoconstriction is not specifically ad-
dressed the guidelines.
Effect of face mask, face mask seal, and patient co-
operation on drug delivery with VHCs
Face masks are used to facilitate drug delivery in young chil-
dren who are incapable of holding a mouthpiece between the
lips and teeth [9]. However, drug delivery is lower when face
mask is used [17, 36]. Children older than 3–4 years of age are
generally able to use VHCwithout masks [9], and most guide-
lines recommend that face mask should be omitted as soon as
children are able to demonstrate good technique [8–11, 13].
A good seal with a minimal leak around the nose, cheeks,
and mouth will ensure inspiration through the VHC and pre-
vents ingress of ambient air between the mask and face [37,
38]. Several in vitro studies have shown that leakage due to
the lack of a tight mask-to-face seal has a large impact on
aerosol delivery [17, 20, 37, 39–41]. Even a minor air leak
between the face and the mask can drastically reduce aerosol
delivery and depending on the location and size of the mask
leak, and drug delivery can drop almost to an undetectable
level [41]. According to Esposito-Festen et al. [41], the lung
dose seems to decrease more rapidly when the mask leak is
located close to the nose relative to a leak near the chin. The
overall design, volume, and degree of adaptability of the face
mask are important factors that influence the fit and mask-to-
face seal as well as the physical dead space of the mask [32].
When pressed against the face, pressure causes compression
of the mask, tightening the contact and reducing the actual
dead space of the mask [42, 43]. However, with increasing
pressure against the face, children are more likely to cry which
again decreases the inhaled dose [44–46].
When aerosol is inhaled during crying, lung deposition
decreases significantly [46, 47]. In a study by Erzinger at al.
[45], lung deposition of radiolabeled drug relative to the total
nominal dose was 0.2–0.3% in children who inhaled with a
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screaming children with a tightly fitted face mask and 4.8–
8.2% in patients inhaling quietly. Approximately 2–5 breaths
per actuation seem to be enough to empty the VHC [23, 25,
48]. However, the optimal number of breaths required to emp-
ty the VHC depends on the child’s Vt, the volume of the VHC
and valve dead space.
Guidelines are in line with the evidence in recommending
the use of face masks for younger children, but they do not
fully endorse good face mask fit or the importance of calming
the child to improve co-operation and drug delivery (Table 2).
Impact of taking each puff separately vs. multiple
puffs simultaneously
Clark and Lipworth [49] measured higher plasma salbutamol
levels per actuation and greater systemic responses after inhal-
ing each puff separately from the Volumatic VHC (750 mL)
compared with either inhaling multiple puffs simultaneously
or taking single puffs with delayed inhalation. Also using the
Volumatic, Barry and O’Callaghan [50] found that compared
with single actuation, double actuation for one inhalation de-
creased drug recovery by 22% per 100 μg actuation and quin-
tuple actuation decreased it by 62% per 100 μg actuation. In
the study by Wildhaber et al. [51], the total amount of
salbutamol delivery from Babyhaler (350 mL) was reduced
by 17% per actuation for two puffs at a time and by 22% per
actuation for five puffs at a time. In the same study the differ-
ences in drug delivery for multiple actuations from the
antistatically treated Babyhaler and the antistatic
Nebuchamber were less pronounced but still statistically sig-
nificant. The effect of multiple actuations may vary depending
on the VHC brand. In the study by Csonka and Lehtimäki
[52], four out of the six VHCs examined showed significantly
poorer performance per actuation with two puffs as opposed
to one puff. The reason for the variable effect of puffs is not
well known, but multiple actuations may influence the overall
aerodynamic environment and drug flow within the chamber.
There is clear evidence that better drug delivery can be
achieved by inhaling each dose separately. Most of the guide-
lines are in line with the evidence, but this should be noted in
every guideline (Table 2).
Electrostatic charge and detergents have variable
effects on drug VHC delivery
Static electricity is an imbalance of electric charges
within or on the surface of a material. Materials that
have a low electrical resistance are called conductive,
since they allow electrons to flow easily across the sur-
face or through the material. Conductive materials—for
example aluminum and steel—are less static compared
with non-conductive materials. Non-conductive mate-
rials, such as plastic or cardboard, are always prone to
build up static charge. The polarity and strength of the
charges differ according to the compound used, surface
roughness, ambient temperature, rinsing, and other prop-
erties. In addition, anti-static coating can reduce the tri-
boelectric effect but cannot completely diminish it. The
most challenging characteristic of the triboelectric effect
is unpredictability.
Many in vitro and in vivo studies have demonstrated
that drug delivery from non-conductive (e.g., polycarbon-
ate or polyester) VHCs that are prone to static electricity is
typically improved by pre-washing in detergent solution
and air-drying, or via other means of antistatic coating
[31, 53–55]. Performance differences exist also between
those plastic VHCs that are marketed by the manufacturer
as antistatic (e.g. acrylonitrile butadiene styrene (ABS))
and even between conductive (e.g. metal) VHCs [19, 31,
52, 55–59]. Reducing the charge by coating the chamber
surface with ionic detergent has been shown to result in an
increase of 50–70% in fine particle (< 6.8 μm) delivery
from a large polycarbonate VHC (Volumatic) [54] as well
as from five small volume plastic (polycarbonate and ABS)
and metal VHCs in vitro [51]. In another study, washing
volumatic with plain water was as effective as an antistatic
lining in reducing the effects of static charge on salbutamol
delivery in vivo [49]. Similarly, the study by Dompeling
et al. [56] found that despite their difference in static prop-
erties, plastic VHCs (Aerochamber and Volumatic) and the
metal Nebuchamber were equally effective regarding the
clinical efficacy of salbutamol in children with asthma. On
the other hand, Csonka and Lehtimäki [52] detected a sig-
nificant reduction in the performance of Babyhaler
(polycarbonate) and A2A (ABS) after detergent washing.
Hatley et al. [60] found that the performance of the
Optichamber Diamond (ABS), when taken out of its orig-
inal packaging and used for the first time, was not influ-
enced by washing in soapy water.
The effect of static charge of VHCs has translated to vari-
able effects on lung deposition and lung function [19, 31,
55–58]. Piérart et al. [31] found that the mean lung deposition
of radiolabeled salbutamol in healthy subjects was 46%
through a detergent-coated volumatic compared with 12%
through an untreated static VHC. A study by Anhøj et al.
[55] reported that the antistatically treated Babyhaler delivered
a significantly higher lung dose than either untreated
Babyhaler or AeroChamber (ABS). In the study by
Dompeling et al. [56] electrostatic charge on plastic VHCs
had no significant influence on the clinical efficacy of
salbutamol in children with asthma. The Nebuchamber (met-
al), Aerochamber (ABS), and Volumatic (polycarbonate)
were equally effective [56]. The in vivo study by Janssens
et al. [57] involving 1-4 years old children detected signifi-
cantly (p < 0.001) higher mean filter dose (41.7 ± 10.1%)
using metal Nebuchamber compared with polycarbonate
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Babyhaler 26.0 ± 4.0%. Another study found no differences in
specific airway resistance or FEV1 following a methacholine
challenge in children administered salbutamol via an untreated
Babyhaler, a detergent washed Babyhaler or a metal
Nebuchamber [58].
Evidence suggests that different chamber materials
have variable electrostatic properties and that VHC han-
dling may significantly affect drug delivery. Some guide-
lines address the issue of VHC static charge (Table 2), but
there are no specific recommendations about the ideal
chamber composition and as to how and with which de-
tergent should the VHCs be pre-treated. Future sponsor-
independent studies are needed to evaluate the clinical
impact of the electrostatic effect and antistatic treatment
of VHCs.
Conclusions
We found strong evidence to support several recommenda-
tions in current guidelines. Face mask should be omitted when
the child can hold the mouthpiece of the VHC tightly between
the lips and teeth. In addition, each puff of salbutamol should
be given separately without delay, i.e., one puff per 2–5
inhalations.
Based on the systematic review, we suggest adding a spe-
cific note to the current guidelines about the impact of coop-
eration during drug administration. Calming the child and
securing a tight face-to-mask seal is critical for successful drug
delivery. Guidelines could benefit from more elaborate in-
structions on drug administration with valved holding cham-
bers in preschool children (Table 3.)
Although some guidelines address the issue of VHC static
charge, there is insufficient data to make recommendations on
ideal chamber material and antistatic treatment. Published data
suggest that different VHCs and their masks cannot be as-
sumed to be equally effective in drug delivery for bronchodi-
lator administration, but there is not enough evidence to make
specific recommendations on the most reliable and effective
VHC delivery system. More research is needed about the op-
timal choice of pMDI+VHC combination for children at dif-
ferent age groups and with different respiratory patterns.
Abbreviations ABS, Acrylonitrile butadiene styrene; ER, Emergency
room; PIFR, Peak inspiratory flow rate; pMDI, Pressurized metered dose
inhalers; RR, Respiratory rate; VHC, Valved holding chambers; Vt, Tidal
volume
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Table 3 Recommendations on how to use a pMDI and VHC in
preschool children
These are general recommendations and the nuances may vary depending
on the child’s age and device model.
General notes:
• Always check that the VHC is intact and the valves are correctly
positioned and working properly.
• Face mask should be used in children younger than three years of age
and for those who are unable to hold the VHC’s mouthpiece between
the lips.
• Tight fit and good seal between the mask and face is essential for drug
delivery. Choose the correct size mask.
• Crying and poor co-operation of the child during inhalation may sig-
nificantly decrease pulmonary drug delivery. Invest in calming the
child but administer the medication as soon as possible.
• Always actuate one puff at a time into the VHC.
Drug delivery step by step
1. Explain to the child, what you are about to do and why. Calm the child
if he/she is agitated.
2. Position the child sitting up straight with face slightly upwards.
Support the child’s body and head gently but firmly. With small
children you may need extra helping hands.
3. Remove the pMDI cap.
4. Shake the pMDI vigorously five times.
5. Hold the pMDI upright and place it firmly into the VHC.
6. Keep the pMDI+VHC unit in a horizontal position and place the face
mask or mouthpiece meticulously:
6.1. In case a face mask is used, make sure the face mask is of correct
size. It should cover the mouth and nose comfortably. Look around the
mask’s perimeter and make sure that the mask is touching the face all
around and there is no leak between the mask and face. Adjust the fit if
necessary.
6.2. If the mask is not needed, place the mouthpiece between the teeth
and make sure the lips are tightly sealed around the mouthpiece
without gaps.
7. If the child is crying or resisting, take some time to calm the child.
8.When the VHC is properly positioned and the child is inhaling calmly,
actuate the pMDI once.
9. Let the child breath for at least five breathing cycles before you remove
the VHC.
10. If additional doses are needed, repeat the whole process from step 4.
onwards.
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